Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 fixed-sequence study of fosmanogepix drug interaction potential and QTc effects in healthy adults
NL-OMON61619Phase 1Recruiting
- Sponsor
- Basilea Pharmaceutica
- Start
- Sep 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fosmanogepix in invasive mycoses, sponsored by Basilea Pharmaceutica. Started Sep 2026; status: recruiting.
02
Drugs
fosmanogepix
03
Conditions
invasive mycoses
Beyond the preview
Go deeper on NL-OMON61619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61619.